清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

医学 改良兰金量表 冲程(发动机) 内科学 安慰剂 临床试验 中风恢复 物理疗法 缺血 缺血性中风 病理 康复 机械工程 替代医学 工程类
作者
Kiyohiro Houkin,Toshiya Osanai,Shinichiro Uchiyama,Kazuo Minematsu,Akihiko Taguchi,Katsuhiko Maruichi,Yoshimasa Niiya,Katsuyuki Asaoka,Yoshihiro Kuga,Katsumi Takizawa,Koichi Haraguchi,Shinichi Yoshimura,Kazumi Kimura,Koji Tokunaga,Atsuo Aoyama,Fusao Ikawa,Chikanori Inenaga,Tatsuya Abé,Atsushi Tominaga,Shinichi Takahashi
出处
期刊:JAMA Neurology [American Medical Association]
被引量:18
标识
DOI:10.1001/jamaneurol.2023.5200
摘要

Importance Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow–derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. Design, Setting, and Participants The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. Exposure Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. Main Outcomes and Measures The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. Results This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, −7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. Conclusions and Relevance In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. Trial Registration ClinicalTrials.gov Identifier: NCT02961504
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
livra1058完成签到,获得积分10
10秒前
Hxq完成签到 ,获得积分10
10秒前
阿曾完成签到 ,获得积分10
21秒前
vitamin完成签到 ,获得积分10
29秒前
dashi完成签到 ,获得积分10
32秒前
无悔完成签到 ,获得积分10
42秒前
LaTeXer应助feng采纳,获得200
53秒前
胡国伦完成签到 ,获得积分10
59秒前
善学以致用应助ceeray23采纳,获得20
1分钟前
wack发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
YifanWang应助科研通管家采纳,获得30
1分钟前
YifanWang应助科研通管家采纳,获得50
1分钟前
CipherSage应助科研通管家采纳,获得10
1分钟前
LeoBigman完成签到 ,获得积分10
2分钟前
文与武完成签到 ,获得积分10
2分钟前
昌莆完成签到 ,获得积分10
2分钟前
xmhxpz完成签到,获得积分10
2分钟前
wack发布了新的文献求助10
3分钟前
3分钟前
搁浅完成签到,获得积分10
3分钟前
zhao完成签到,获得积分10
3分钟前
Hua完成签到,获得积分0
3分钟前
dingding完成签到,获得积分10
3分钟前
月儿完成签到 ,获得积分10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
YifanWang应助科研通管家采纳,获得10
3分钟前
YifanWang应助科研通管家采纳,获得10
3分钟前
YifanWang应助科研通管家采纳,获得40
3分钟前
蔡从安发布了新的文献求助10
3分钟前
糖醋里脊加醋完成签到 ,获得积分10
3分钟前
欢喜白亦完成签到 ,获得积分10
3分钟前
KINGAZX完成签到 ,获得积分10
4分钟前
luckyalias完成签到 ,获得积分10
4分钟前
zhangsan完成签到,获得积分10
4分钟前
4分钟前
雪白小丸子完成签到,获得积分10
4分钟前
www发布了新的文献求助30
4分钟前
蔡从安发布了新的文献求助10
4分钟前
脑洞疼应助蔡从安采纳,获得10
4分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990603
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805229
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234